Cellectis : Corporate Presentation January 2021

COMMITMENT TO A CURE

Investor Presentation

January 2021

cellectis.com

FORWARD-LOOKING STATEMENTS

This presentation contains "forward-looking" statements that are based on our management's current expectations and assumptions and on information currently available to management.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.

Factors that may cause actual results to differ from those in any forward-looking statement, include the duration and severity of the COVID-19 pandemic and responsive measures; inconclusive clinical trial results or clinical trials failing to achieve one or more endpoints; early data not being repeated in ongoing or future clinical trials; failures to secure required regulatory approvals; disruptions from failures by third-parties on whom we rely in connection with our clinical trials; delays or negative determinations by regulatory authorities; changes or increases in oversight and regulation; increased competition;

manufacturing delays problems; inability to achieve enrollment disagreements with our collaboration partners of collaboration partners to pursue product legal challenges or intellectual property disputes; disruptions to access to raw materials or starting material.

Further information on risks and factors that may affect company business and financial performance, is included in our annual report on form 20-F and the financial report (including the management report) for the year ended December 31, 2019 and subsequent filings Cellectis makes with the Securities and Exchange Commission from time to time.

Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Cellectis proprietary information. Not to be copied, distributed or used without Cellectis' prior written consent.

P2

WRITING THE HISTORY OF ALLOGENEIC CAR T-CELLS

21 years	9 years	7 clinical trials
of expertise in	of experience in allogeneic	ongoing as of 2020;
gene editing	CAR-T manufacturing	3 Cellectis-sponsored
		4 partnered

INVENTORS / PIONEERS OF GENE EDITING & ALLOGENEIC CAR T-CELLS

In 2012 . .

Mission to develop allogeneic CAR T-cells begins

In 2015 . .

First-in-man compassionate use of an allogeneic CAR-T product candidate occurs

P3

ADVANTAGES OF ALLOGENEIC VS. AUTOLOGOUS CAR-T

Autologous process:		Manufacturing variability + several weeks before treatment is available

1.	2.	3.	4.
CANCER TREATMENT	CANCER	MANUFACTURING OF A	INDIVIDUAL CAR-T
DECISION	PATIENT APHERESIS	SINGLE PATIENT	THERAPY
		PRODUCT

Allogeneic process:

		Consistent manufacturing + quality		Immediate treatment

HEALTHY DONOR	SCALABLE	MASS PRODUCED	1.	2.
APHERESIS	MANUFACTURING	ALLOGENEIC CAR-T	CANCER TREATMENT	OFF-THE-SHELF
	OF 100+ DOSES/BATCH	THERAPIES	DECISION	CAR-T THERAPY

• TIME SAVED
• COST EFFECTIVE
• MARKET ACCESS

P4